5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in fat cell metabolism. Technically it is not a peptide, but it is sold in the peptide market and used by the same community. By inhibiting NNMT, it may increase NAD+ levels in fat tissue and shift metabolism toward fat burning. Think of it as targeting fat cells at the enzyme level rather than through appetite suppression.

How does NNMT inhibition work? NNMT is overexpressed in obesity and metabolic disease. It consumes SAM (S-adenosylmethionine) and produces 1-methylnicotinamide, depleting methyl donors and slowing metabolism. By blocking NNMT, 5-Amino-1MQ preserves SAM and raises NAD+ levels. Higher NAD+ activates sirtuins which regulate mitochondrial biogenesis and fat oxidation. The result is fat cells that burn more energy and become less efficient at storing fat.

What does the research actually show? Early stage. Promising animal data on fat reduction without calorie restriction. No large human clinical trials yet. In preclinical mouse studies, it prevented obesity even when subjects were fed a high-fat diet. The mechanism is well-understood but the clinical evidence in humans is thin. Position it honestly as an interesting research compound, not a proven weight loss drug.

Unlike GLP-1 peptides that work by suppressing appetite, 5-Amino-1MQ targets metabolism at the cellular level. Semaglutide and tirzepatide make you eat less. 5-Amino-1MQ makes fat cells burn more. Some users stack them. The evidence for stacking is anecdotal, not clinical. If you want to combine approaches, start with one compound first and add the second after a few weeks.

5-Amino-1MQ is available in both oral capsule form and injectable form. Oral capsules are more common because most users who want to inject already have GLP-1s for that purpose. In Philippines, it is available research-grade. Often comes in capsule form rather than injectable, which makes it more accessible for users who do not want to inject. For verified suppliers, see the supply index. Verify purity via the COA guide. For legal context, see the peptide legality guide.

For enhanced fat loss protocols, 5-Amino-1MQ is often combined with retatrutide or tirzepatide. Users also stack it with AOD-9604 for targeting stubborn fat areas. The combination of appetite suppression (GLP-1) plus cellular fat burning (5-Amino-1MQ) is popular in the biohacking weight loss community.

NNMT Inhibition: NNMT is overexpressed in obesity and metabolic disease. It consumes SAM and produces 1-methylnicotinamide, depleting methyl donors and slowing metabolism. By blocking NNMT, 5-Amino-1MQ preserves SAM and raises NAD+ levels.

NAD+ Elevation: Higher NAD+ activates sirtuins (particularly SIRT1 and SIRT3) which regulate mitochondrial biogenesis, fat oxidation, and energy expenditure. This effectively raises the metabolic rate of fat cells.

Adipocyte Reprogramming: Preclinical data shows 5-Amino-1MQ can cause fat cells to take on characteristics of "beige" fat — a more metabolically active form that burns energy through thermogenesis rather than storing it.

• 01Increased fat oxidation without appetite suppression
• 02Boosts NAD+ levels, supporting cellular energy and longevity
• 03May reduce stubborn fat (visceral and subcutaneous)
• 04Potential synergy with GLP-1 peptides for enhanced weight loss
• 05Improves metabolic health markers in preclinical models
• 06Oral bioavailability available (capsule form)
• 07Anti-aging potential via NAD+ and sirtuin activation

Always start at the lowest effective dose and titrate up gradually.

See our community-verified supplier list with COA verification and cold-chain shipping to the Philippines.